 Oncogene Proteins
"Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins coded by oncogenes. They include proteins resulting from the fusion of an oncogene and another gene (ONCOGENE PROTEINS, FUSION).
| Descriptor ID |
D015513
|
| MeSH Number(s) |
D12.776.624.664
|
| Concept/Terms |
Oncogene Proteins- Oncogene Proteins
- Proteins, Oncogene
- Oncogene Products
- Products, Oncogene
- Oncoproteins
- Oncogene Product
- Product, Oncogene
- Oncogene Protein
- Protein, Oncogene
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Proteins".
This graph shows the total number of publications written about "Oncogene Proteins" by people in this website by year, and whether "Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 3 | 0 | 3 | | 1999 | 2 | 1 | 3 | | 2000 | 1 | 0 | 1 | | 2002 | 2 | 1 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 2 | 0 | 2 | | 2009 | 2 | 1 | 3 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 3 | 4 | | 2012 | 2 | 2 | 4 | | 2013 | 1 | 3 | 4 | | 2014 | 0 | 1 | 1 | | 2015 | 2 | 1 | 3 | | 2016 | 2 | 0 | 2 | | 2017 | 2 | 1 | 3 | | 2018 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2020 | 2 | 0 | 2 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Oncogene Proteins" by people in Profiles.
-
Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
-
Santos-Cortez RLP, Yarza TKL, Bootpetch TC, Tantoco MLC, Mohlke KL, Cruz TLG, Chiong Perez ME, Chan AL, Lee NR, Tobias-Grasso CAM, Reyes-Quintos MRT, Cutiongco-de la Paz EM, Chiong CM. Identification of Novel Candidate Genes and Variants for Hearing Loss and Temporal Bone Anomalies. Genes (Basel). 2021 04 13; 12(4).
-
Northey JJ, Barrett AS, Acerbi I, Hayward MK, Talamantes S, Dean IS, Mouw JK, Ponik SM, Lakins JN, Huang PJ, Wu J, Shi Q, Samson S, Keely PJ, Mukhtar RA, Liphardt JT, Shepherd JA, Hwang ES, Chen YY, Hansen KC, Littlepage LE, Weaver VM. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217. J Clin Invest. 2020 11 02; 130(11):5721-5737.
-
Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. J Pathol Clin Res. 2020 10; 6(4):252-262.
-
Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019 06; 16(6):341-355.
-
Ng TL, Morgan RL, Patil T, Barón AE, Smith DE, Ross Camidge D. Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. Lung Cancer. 2018 12; 126:112-118.
-
Arora M, Spencer SL. A Cell-Cycle "Safe Space" for Surviving Chemotherapy. Cell Syst. 2017 09 27; 5(3):161-162.
-
Mor-Vaknin N, Saha A, Legendre M, Carmona-Rivera C, Amin MA, Rabquer BJ, Gonzales-Hernandez MJ, Jorns J, Mohan S, Yalavarthi S, Pai DA, Angevine K, Almburg SJ, Knight JS, Adams BS, Koch AE, Fox DA, Engelke DR, Kaplan MJ, Markovitz DM. DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. Nat Commun. 2017 02 06; 8:14252.
-
Law PJ, Sud A, Mitchell JS, Henrion M, Orlando G, Lenive O, Broderick P, Speedy HE, Johnson DC, Kaiser M, Weinhold N, Cooke R, Sunter NJ, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Carmichael J, Bailey JR, Pratt G, Rahman T, Pepper C, Fegan C, von Strandmann EP, Engert A, Försti A, Chen B, Filho MI, Thomsen H, Hoffmann P, Noethen MM, Eisele L, Jöckel KH, Allan JM, Swerdlow AJ, Goldschmidt H, Catovsky D, Morgan GJ, Hemminki K, Houlston RS. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Sci Rep. 2017 01 23; 7:41071.
-
Guest ST, Kratche ZR, Irish JC, Wilson RC, Haddad R, Gray JW, Garrett-Mayer E, Ethier SP. Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. Oncotarget. 2016 Jun 14; 7(24):36138-36153.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|